Histone deacetylase inhibitors and hemoglobin F induction in β-thalassemia

International Journal of Biochemistry and Cell Biology

Volumn 40, Issue 11, 2008, Pages 2341-2347

  Migliaccio, Anna Rita ^a,b   Rotili, Dante ^c   Nebbioso, Angela ^d   Atweh, George ^a   Mai, Antonello ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Globin locus; Thalassemia; Hemoglobin F induction; Histone deacetylase inhibitors

Indexed keywords

AZACITIDINE; BETA GLOBIN; CYTARABINE; HEMOGLOBIN F; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; VINBLASTINE;

ACETYLATION; BETA THALASSEMIA; CHROMATIN STRUCTURE; CYTOTOXICITY; DNA DAMAGE; DNA METHYLATION; DRUG EFFICACY; DRUG SAFETY; ENZYME SYNTHESIS; ERYTHROID CELL; GENE EXPRESSION; GENOMICS; HUMAN; SHORT SURVEY; SICKLE CELL ANEMIA;

ANEMIA, SICKLE CELL; ANTINEOPLASTIC AGENTS; BETA-THALASSEMIA; CHROMATIN; EPIGENESIS, GENETIC; ERYTHROCYTES; FETAL HEMOGLOBIN; HISTONE DEACETYLASES; HUMANS; MOLECULAR STRUCTURE;

EID: 48349094044     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2008.04.024     Document Type: Short Survey

References (29)

1. Aerbajinai W., Zhu J., Gao Z., Chin K., and Rodgers G.P. Thalidomide induces γ-globin gene expression through increased reactive oxygen species-mediated p38 MAPK signalling and histone H4 acetylation in adult erythropoiesis. Blood 110 (2007) 2864-2871
2. Atweh G.F., Sutton M., and Nassif I. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood 93 (1999) 1790-1797
3. Atweh G.F., and Schechter A.N. Pharmacologic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease. Curr Opin Hematol 8 (2001) 123-130
4. Bradai M., Abad M.T., Pissard S., Lamraoui F., Skopinski L., and De Montalembert M. Hydroxyurea can eliminate transfusion requirements in children with severe (-thalassemia. Blood 102 (2003) 1529-1530
5. Cao H. Pharmacological induction of fetal hemoglobin synthesis using histone deacetylase inhibitors. Hematology 9 (2004) 223-233
6. Charache S., Terrin M.L., and Moore R.D. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 332 (1995) 1317-1322
7. Comi P., Ottolenghi S., Giglioni B., Migliaccio G., Migliaccio A.R., Bassano E., et al. Bromodeoxyuridine treatment of normal adult erythroid colonies: an in vitro model for reactivation of human fetal globin genes. Blood 68 (1986) 1036-1041
8. Constantoulakis P., Knitter G., and Stamatoyannopoulos G. On the induction of fetal hemoglobin by butyrates: in vivo and in vitro studies with sodium butyrate and comparison of combination treatments with 5-AzaC and AraC. Blood 74 (1989) 1963-1971
9. De Ruijter A.J., van Gennip A.H., Caron H.N., Kemp S., and van Kuilenburg A.B. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370 (2003) 737-749
10. Fathallah H., Weinberg R.S., Galperin Y., Sutton M., and Atweh G.F. Role of epigenetic modifications in normal globin gene regulation and butyrate-mediated induction of fetal hemoglobin. Blood 110 (2007) 3391-3397
11. Felsenfeld G., and Groundine M. Controlling the double helix. Nature 421 (2003) 448-453
12. Forsberg E.C., Downs K.M., Christensen H.M., Im H., Nuzzi P.A., and Bresnick E.H. Developmentally dynamic histone acetylation pattern of a tissue specific chromatin domain. Proc Natl Acad Sci USA 97 (2000) 14494-14499
13. Hassig C.A., and Schreiber S.L. Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr Opin Chem Biol 1 (1997) 300-308
14. Mai A., Jelicic K., Rotili D., Di Noia A., Alfani E., Valente S., et al. Identification of two new synthetic histone deacetylase inhibitors that modulate globin gene expression in erythroid cells from normal donors and thalassemic patients. Mol Pharmacol 72 (2007) 1111-1123
15. Mai A., Massa S., Pezzi R., Simeoni S., Rotili D., Nebbioso A., et al. Class II (IIa)-selective histone deacetylase inhibitors.1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxamides. J Med Chem 48 (2005) 3344-3353
16. Mai A., Massa S., Rotili D., Cerbara I., Pezzi R., Valente S., et al. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev 25 (2005) 261-309
17. Mankidy R., Faller D.V., Mabaera R., Lowrey C.H., Boosalis M.S., White G.L., et al. Short-chain fatty acids induce γ-globin gene expression by displacement of a HDAC3-NCoR repressor complex. Blood 108 (2006) 3179-3186
18. Mavilio F., Giampaolo A., Carè A., Migliaccio G., Calandrini M., Russo G., et al. Molecular mechanisms of human hemoglobin switching: selective undermethylation and expression of globin genes in embryonic, fetal, and adult erythroblasts. Proc Natl Acad Sci USA 80 (1983) 6907-6911
19. Minucci S., and Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6 (2006) 38-51
20. Noguchi C.T., Rodgers G.P., Serjeant G., and Schechter A.N. Levels of fetal haemoglobin necessary for the treatment of sickle cell disease. N Engl J Med 318 (1988) 96-99
21. Olivieri N.F. The beta-thalassemias. N Engl J Med 341 (1999) 99-109
22. Papayannopoulou T., Abkowitz J., D'Andrea A., and Migliaccio A.R. Biology of erythropoiesis, erythroid differentiation and maturation. In: Hoffman R., Benz E.J., Shattil S.J., Furie B., Cohen H.J., Silberstein L.E., and Mc Glave P. (Eds). Hematology: basic principles and practice. 4th ed. (2005), Elsevier, Philadelphia, PA, USA 267-288
23. Perrine S.P., Rudolph A., and Faller D.V. Butyrate infusions in the ovine fetus delay the biologic clock for globin gene switching. Proc Natl Acad Sci USA 85 (1988) 8540-8542
24. Perrine S.P., Ginder G.D., Faller D.V., Dover G.H., Ikuta T., Witkowska H.E., et al. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the β-globin disorders. N Engl J Med 328 (1993) 81-86
25. Sher G.D., Ginder G.D., Little J., Yang S., Dover G.J., and Olivieri N.F. Extended therapy with intravenous arginine butyrate in patients with β-hemoglobinopathies. N Engl J Med 332 (1995) 1606-1610
26. Stamatoyannopoulos G., and Grosveld F. Hemoglobin switching. In: Stamatoyannopoulos G., Majerus P.W., Perlmutter R.M., and Varmus H. (Eds). The molecular basis of blood diseases. 3rd ed. (2001), W.B. Saunders Publishing Co., Philadelphia 135-182
27. Veith R., Galanello R., Papayannopoulou T., and Stamatoyannopoulos G. Stimulation of F-cell production in patients with sickle-cell anemia treated with cytarabine or hydroxyurea. N Engl J Med 313 (1985) 1571-1575
28. Weinberg R.S., Ji X., Sutton M., Perrine S., Galperin Y., Li Q., et al. Butyrate increases the efficiency of translation of gamma-globin mRNA. Blood 105 (2005) 1807-1809
29. Yin W., Barkess G., Fang X., Xiang P., Cao H., Stamatoyannopoulos G., et al. Histone acetylation at the human β-globin locus changes with developmental age. Blood 110 (2007) 4101-4107